Cargando…
Uneventful octreotide LAR therapy throughout three pregnancies, with favorable delivery and anthropometric measures for each newborn: a case report
INTRODUCTION: The safety of octreotide use, in its short-acting preparation, in pregnancy is still unclear. This report provides the first documentation of uneventful octreotide LAR use during three pregnancies in a woman with bronchial carcinoid-associated adrenocorticotropic hormone-dependent Cush...
Autores principales: | Naccache, Deeb Daoud, Zaina, Adnan, Shen-Or, Zila, Armoni, Michal, Kontogeorgos, George, Yahia, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169497/ https://www.ncbi.nlm.nih.gov/pubmed/21846347 http://dx.doi.org/10.1186/1752-1947-5-386 |
Ejemplares similares
-
Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023) -
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015) -
Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011) -
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011) -
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)